IC
STRO icon

Ikarian Capital’s Sutro Biopharma STRO Stock Holding History

Ikarian Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20,000
Closed -$4.55M – 281
2021
Q1 		$4.55M Buy
+20,000
New +$4.75M 0.15% 127

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Ikarian Capital's STRO Position: Q4 2021 in Review

Ikarian Capital sold out of Sutro Biopharma (STRO) in Q4 2021, closing a stake of 13,458 shares — an estimated $2.54M sold.

Ikarian Capital first reported a position in STRO in Q3 2020 and held it in 5 quarters. The position peaked at $13.4M in Q4 2020. 117 funds tracked by Wall St. Rank hold STRO as of Q4 2021.

  • Ikarian Capital reported no remaining Sutro Biopharma position as of Q4 2021 after selling out during the quarter.
  • Ikarian Capital sold 13,458 Sutro Biopharma shares in Q4 2021, an estimated $2.54M.
  • Ikarian Capital first reported a position in Sutro Biopharma in Q3 2020 and held it in 5 quarters.
  • Ikarian Capital's Sutro Biopharma position peaked at $13.4M in Q4 2020.
  • 117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2021.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.